These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8593170)

  • 1. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?
    De Clercq E; Balzarini J
    Farmaco; 1995 Nov; 50(11):735-47. PubMed ID: 8593170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-nucleoside reverse transcriptase inhibitors].
    Joly V; Yeni P
    Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1, 2, 3-current ways to fight HIV.
    Vazquez E
    Posit Aware; 1998; 9(6):31-3. PubMed ID: 11366478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle.
    De Clercq E
    Biomed Pharmacother; 1996; 50(5):207-15. PubMed ID: 8949401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
    Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
    Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential benefits of nucleoside analogue regimens in failing therapy.
    Geretti AM
    J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J
    Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of new reverse transcriptase inhibitors].
    Kodama E
    Nihon Rinsho; 2002 Apr; 60(4):775-9. PubMed ID: 11968787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.